{"nctId":"NCT02392234","briefTitle":"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation","startDateStruct":{"date":"2015-03"},"conditions":["Cystic Fibrosis"],"count":248,"armGroups":[{"label":"VX-661/Ivacaftor combination","type":"EXPERIMENTAL","interventionNames":["Drug: VX-661/Ivacaftor","Drug: Ivacaftor","Drug: Placebo matched to Ivacaftor"]},{"label":"Ivacaftor monotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Ivacaftor","Drug: Placebo matched to VX-661/ ivacaftor"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo matched to VX-661/ ivacaftor","Drug: Placebo matched to Ivacaftor"]}],"interventions":[{"name":"VX-661/Ivacaftor","otherNames":["VX-661+VX-770"]},{"name":"Ivacaftor","otherNames":["IVA, VX-770"]},{"name":"Placebo matched to VX-661/ ivacaftor","otherNames":[]},{"name":"Placebo matched to Ivacaftor","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Heterozygous for F508del-CFTR and a second allele with a CFTR mutation predicted to have residual function\n* Forced Expiratory Volume in 1 Second (FEV1) greater than or equal to (≥) 40 percent (%) and less than or equal to (≤) 90% of predicted normal for age, sex, and height during screening\n* Sweat chloride value ≥60 millimole per liter (mmol/L) during screening OR as documented in the participant's medical record\n* Stable CF disease as judged by the investigator\n\nExclusion Criteria:\n\n* History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant\n* An acute upper or lower respiratory infection, pulmonary exacerbation\n* History of solid organ or hematological transplantation\n* Ongoing or prior participation in an investigational drug study (including studies investigating VX-661, lumacaftor \\[VX-809\\], and/or ivacaftor) within 30 days of screening\n* Pregnant and nursing females\n* Sexually active participants of reproductive potential who are not willing to follow the contraception requirements","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":null},{"groupId":"OG001","value":"4.4","spread":null},{"groupId":"OG002","value":"6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Study Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Week 4 and Week 8","description":"The CFQ-R assessed respiratory symptoms on a scale with scores ranging from 0 to 100; where higher scores indicated fewer symptoms and better health-related quality of life.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":null},{"groupId":"OG001","value":"8.7","spread":null},{"groupId":"OG002","value":"10.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Change From Study Baseline in ppFEV1 at Average of Week 4 and Week 8","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":null},{"groupId":"OG001","value":"7.9","spread":null},{"groupId":"OG002","value":"11.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Study Baseline in Sweat Chloride at Average of Week 4 and Week 8","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"-4.9","spread":null},{"groupId":"OG002","value":"-9.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661), IVA and IVA Metabolite (M1 IVA) After Administration of VX-661/IVA Combination Therapy","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2370","spread":"1330"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5230","spread":"1940"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"909","spread":"530"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2010","spread":"1050"}]}]}]},{"type":"SECONDARY","title":"Ctrough of IVA and IVA Metabolite (M1 IVA) After Administration of IVA Monotherapy","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"696","spread":"435"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1550","spread":"808"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":162},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Headache","Haemoptysis","Sputum increased"]}}}